



117W
COTZ

In re Application of: Jean MARTINEZ et al.

Confirmation No.: 5326

Patent No.: 6,861,409 B2

Application No.: 09/880,498

Patent Date: March 1, 2005

Filing Date: June 13, 2001

For: GROWTH HORMONE
SECRETAGOGUES

Attorney Docket No.: 87264-100

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are listed on the attached Form PTO-1050, submitted in duplicate. The corrections requested are as follows:

Column 23:

Line 24 (claim 1, line 1), after "A compound", delete "which is" and insert -- having the following structure --.

Line 43 (claim 2, line 1), after "A pharmaceutical composition, comprising", delete "a" and insert -- the --.

Column 24:

Line 27 (claim 5, line 3), after "a therapeutically effective amount of", delete "a" and insert -- the --.

Line 32 (claim 6, line 3), after "therapeutically effective amount of", delete "a" and insert -- the --.

Line 37 (claim 7, line 3), after "effective amount of", delete "a" and insert -- the --.

Line 42 (claim 8, line 4), after "amount of", delete "a" and insert -- the --.

Support for each of the above corrections appears in the Examiner's Amendment attached to the Notice of Allowability mailed January 9, 2004.

As the requested corrections are for errors that were made by the Office, no fee is believed to be due for this request. Should any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

3/22/05
Date

Jeffrey A. Wolfson
Jeffrey A. Wolfson (Ref. No. 42,234)

WINSTON & STRAWN LLP
Customer No. 28765

202-282-5770

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO.: 6,861,409 B2
DATED: March 1, 2005
INVENTORS: Martinez et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 23:

Line 24, after "A compound", delete "which is" and insert -- having the following structure --.

Line 43, after "A pharmaceutical composition, comprising", delete "a" and insert -- the --.

Column 24:

Line 27, after "a therapeutically effective amount of", delete "a" and insert -- the --.

Line 32, after "therapeutically effective amount of", delete "a" and insert -- the --.

Line 37, after "effective amount of", delete "a" and insert -- the --.

Line 42, after "amount of", delete "a" and insert -- the --.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 1

<210> SEQ ID NO 1

<211> LENGTH: 28

<212> TYPE: PRT

<213> ORGANISM: rat

<220> FEATURE:

<221> NAME/KEY: MOD_RES

<222> LOCATION: (3)..(3)

<223> OTHER INFORMATION: o-n-octanoyl


<400> SEQUENCE: 1

Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys
 1 5 10 15

Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg
 20 25

What is claimed is:

1. A compound ~~which is~~ having the following structure:



2. A pharmaceutical composition, comprising a compound of claim 1.

3. The composition of claim 2, in combination with a pharmaceutically acceptable carrier.

4. The composition of claim 2, in combination with an additional growth hormone secretagogue.

5. A method for elevating the plasma level of growth hormone in a mammal comprising administering to a mammal a therapeutically effective amount of a compound according to claim 1 so as to elevate the plasma level of growth hormone.

6. A method for the treatment of growth hormone secretion deficiency comprising administering to a mammal a therapeutically effective amount of a compound according to claim 1 so as to treat the growth hormone secretion deficiency.

7. A method for the treatment of growth retardation in a child comprising administering to a patient a therapeutically effective amount of a compound according to claim 1 so as to treat the growth retardation.

8. A method for the treatment of metabolic disorders associated with growth hormone secretion deficiency comprising administering to a patient a therapeutically effective amount of a compound according to claim 1 so as to treat the metabolic disorder.

9. The compound of claim 1 in the form a salt thereof.

* * * * *